Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|12|7|1056-1081

ISSN： 1389-4501

Source： Current Drug Targets, Vol.12, Iss.7, 2011-06, pp. : 1056-1081

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibition of phosphatidylinositol 3-kinase

By Zahradka P.  

Expert Opinion on Therapeutic Targets, Vol. 2, Iss. 1, 1998-07 ,pp. : 97-99

Informa Healthcare

Access to resources Recommend Favorite

Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery

By Maira Sauveur-Michel   Voliva Charles   Garcia-Echeverria Carlos  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 2, 2008-02 ,pp. : 223-238

Informa Healthcare

Access to resources Recommend Favorite

Halenaquinone, a novel phosphatidylinositol 3-kinase inhibitor from a marine sponge, induces apoptosis in PC12 cells

By Fujiwara H.   Matsunaga K.   Saito M.   Hagiya S.   Furukawa  

European Journal of Pharmacology, Vol. 413, Iss. 1, 2001-02 ,pp. : 37-45

Elsevier

Access to resources Recommend Favorite

Potent Phosphatidylinositol 3-Kinase Inhibitors and Their Biology

By  

Current Drug Discovery Technologies, Vol. 11, Iss. 2, 2014-06 ,pp. : 113-126

Bentham Science Publishers

Access to resources Recommend Favorite

Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer?

By Fujino H.   Regan J.W.  

Trends in Pharmacological Sciences, Vol. 24, Iss. 7, 2003-07 ,pp. : 335-340

Elsevier

Access to resources Recommend Favorite